SCHEMBL16307308

SCHEMBL16307308

NS(=O)(=O)N[C@H]1CCc2cc(Cl)cc(F)c21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 8/20 0.46
CA2 P00918 8/20 0.46
BDKRB1 P46663 3/20 0.37
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
P2RX7 Q99572 3/20 0.33
CA12 O43570 2/20 0.33
CA7 P43166 2/20 0.33
CA9 Q16790 2/20 0.33
CA14 Q9ULX7 2/20 0.33
TRPV1 Q8NER1 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
NOS2 P35228 1/20 0.31
ACLY P53396 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16290590 1.00 CA1 (0.46) CA1CA2BDKRB1PDE4APDE4B
SCHEMBL16290310 0.83 CA1 (0.47) CA1CA2PDE4APDE4BPDE4C
SCHEMBL16290515 0.80 CA1 (0.46) CA1CA2P2RX7CA12CA7
SCHEMBL16307309 0.79 CA2 (0.59) CA1CA2CA12CA7CA9
SCHEMBL16307317 0.77 CA1 (0.42) CA1CA2KMT2ATDP1ACLY
SCHEMBL16290339 0.77 CA1 (0.42) CA1CA2KMT2ATDP1ACLY
SCHEMBL18710441 0.77 BDKRB1 (0.36) BDKRB1P2RX7
SCHEMBL16290591 0.77 BDKRB1 (0.36) BDKRB1P2RX7KMT2A
SCHEMBL16290717 0.76 CA1 (0.46) CA1CA2KMT2ATDP1
SCHEMBL18710482 0.76 CA1 (0.46) CA1CA2KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2865663-B1 NOVEL INDANESULFAMIDE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2017-04-05 EP disclosed
EP-2865663-A1 NOVEL INDANESULFAMIDE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2015-04-29 EP disclosed
US-9018260-B2 Indanesulfamide derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-28 US disclosed
US-9018260-B2 Indanesulfamide derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-28 US disclosed
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-12-18 US disclosed
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES SCN1A, SCN7A, SCN2A CA1 219/4885CA2 315/4885BDKRB1 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.